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Cell non-autonomous regulation of
hepatic IGF-1 and neonatal growth
by Kinase Suppressor of Ras 2
(KSR2)
Lili Guo1, Diane L. Costanzo-Garvey1, Deandra R. Smith1, Megan E. Zavorka2,
Megan Venable-Kang2, Richard G. MacDonald2,3 & Robert E. Lewis1,3
Individuals with poor postnatal growth are at risk for cardiovascular and metabolic problems as adults.
Here we show that disruption of the molecular scaffold Kinase Suppressor of Ras 2 (KSR2) causes
selective inhibition of hepatic GH signaling in neonatal mice with impaired expression of IGF-1 and
IGFBP3. ksr2−/− mice are normal size at birth but show a marked increase in FGF21 accompanied by
reduced body mass, shortened body length, and reduced bone mineral density (BMD) and content
(BMC) first evident during postnatal development. However, disrupting FGF21 in ksr2−/− mice does
not normalize mass, length, or bone density and content in fgf21−/−ksr2−/− mice. Body length, BMC
and BMD, but not body mass, are rescued by infection of two-day-old ksr2−/− mice with a recombinant
adenovirus encoding human IGF-1. Relative to wild-type mice, GH injections reveal a significant
reduction in JAK2 and STAT5 phosphorylation in liver, but not in skeletal muscle, of ksr2−/− mice.
However, primary hepatocytes isolated from ksr2−/− mice show no reduction in GH-stimulated STAT5
phosphorylation. These data indicate that KSR2 functions in a cell non-autonomous fashion to regulate
GH-stimulated IGF-1 expression in the liver of neonatal mice, which plays a key role in the development
of body length.
Low birth weight and neonatal growth defects are associated with obesity and the development of insulin resistance in adult humans1–6. Environmental factors like poor nutrition during fetal development and early life may
activate mechanisms that impose a nutritionally thrifty phenotype upon individuals, promoting survival in the
short term, but increasing susceptibility to type 2 diabetes (T2D) in the long term1,3. Various animal models have
been developed to identify the molecular mechanisms that drive this metabolic reprogramming7,8. Most animal
models require dietary, pharmacological, or surgical manipulation of the mother to limit nutrition or oxygen,
which disrupts fetal development and suppresses the birth weight of pups. Modulating nutrition during the early
neonatal period alters the development of central nervous system pathways critical to the development of normal
adiposity and insulin sensitivity in adults9,10. In fact, the suckling period in rodents is critical for the development
of pancreatic islets and the hypothalamus8,11. There is a paucity of genetic models, however, that reflect the effects
of pre- or postnatal programming on the development of basal metabolism. Kinase suppressor of Ras 2 (KSR2)
is required for normal neonatal growth as well as the development of normal energy balance and glucose homeostasis in the adult12,13. KSR2 knockout (ksr2−/−) mice may serve as a potential genetic model for assessing the
importance of the neonatal period in the development of normal metabolism.
Kinase suppressor of Ras 1 and 2 (KSR1 and KSR2) are scaffold proteins for the Raf/MEK/ERK MAPK signaling pathway that mediates signaling downstream of cell-surface receptors14–16. KSR2, first discovered in C. elegans,
is required for Ras-mediated signaling in germline meiotic progression, and functions redundantly with KSR1
in the development of the excretory system, hermaphrodite vulva, and male spicules16. Through an interaction
with calcineurin, KSR2 mediates calcium-regulated activation of the ERK pathway. The KSR2 interaction with
calcineurin is involved in neurite outgrowth17 and is required for optimal calcium uptake in white blood cells18.
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In addition to its role as a scaffold for ERK signaling, KSR2 also interacts with and regulates the energy sensor
5′-AMP-activated protein kinase (AMPK), an interaction that is a critical contributor to energy balance12.
Humans with KSR2 mutations exhibit childhood hyperphagia, early-onset obesity, reduced metabolic rate, and
severe insulin resistance19. ksr2−/− mice recapitulate the key metabolic characteristics of humans with KSR2
mutations; ksr2−/− mice are obese, insulin-resistant, and exhibit a reduced metabolic rate12. These observations
suggest a conserved function of KSR2 between rodents and humans. The molecular mechanisms regulating
KSR2-dependent insulin resistance and obesity are unknown.
In addition to obesity and severe insulin resistance in mature animals, ksr2−/− mice grow more slowly than
their wild type (WT) littermates during the neonatal period, yet they have a normal birth weight12. Postnatal
growth is primarily regulated by growth hormone (GH)-induced insulin-like growth factor 1 (IGF-1)20. GH is
secreted by the pituitary under the control of growth hormone-releasing hormone (GHRH) and somatostatin,
which are both produced and secreted by the hypothalamus. GH induces IGF-1 expression and its secretion
from peripheral tissues including the liver, muscle, fat, and bone. The main source of circulating IGF-1 is the
liver. Circulating IGF-1, together with locally secreted IGF-1, promotes body growth20. In response to poor
nutrition, the body induces GH resistance in order to decrease circulating IGF-1 and reduce growth and energy
demand21. Recent studies suggest that increased fibroblast growth factor 21 (FGF21), a metabolic hormone primarily produced by liver, is an important factor in the regulation of liver-specific GH resistance in response to
poor nutrition22.
We investigated the molecular basis for the neonatal growth defects in ksr2−/− mice. Here we show that,
although GH levels are normal in ksr2−/− mice at postnatal day 17 (PN17), serum IGF-1 is decreased at both PN6
and PN17 in ksr2−/− mice. Serum FGF21 and hepatic FGF21 mRNA levels are increased in neonatal ksr2−/− mice
compared to their WT littermates. However, FGF21 disruption fails to restore normal body weight to neonatal
ksr2−/− mice. Exogenous IGF-1 rescued bone development, but also failed to restore normal body weight to
neonatal ksr2−/− mice. GH-induced phosphorylation of hepatic STAT5b and JAK2 are decreased in ksr2−/− neonates in vivo, but not in isolated hepatocytes, suggesting that the GH signaling is modulated by KSR2 via a cell
non-autonomous mechanism. Postnatal growth and adult-onset insulin resistance may be affected by similar
environmental and genomic influences4. Elucidating the mechanisms underlying growth defects in neonatal
ksr2−/− mice may help reveal mechanisms critical to the development of normal adult energy balance and glucose
homeostasis.

Results

Neonatal ksr2−/− mice have growth defects and decreased IGF-1 levels. Though born normal in

size, ksr2−/− mice are only 80% and 70% the weight of WT littermates at PN6 and PN17, respectively (Fig. 1a,b).
The growth defect is more severe in ksr2−/− animals with the DBA/1LacJ background, which are about 50% the
weight of their WT littermates at ages PN14-17 12. The nose-to-anus length is also decreased in ksr2−/− mice compared to WT control mice at five weeks of age (Fig. 1c). Bone mineral density (BMD) and bone mineral content
(BMC) are also significantly lower in ksr2−/− mice relative to WT littermates at five weeks of age (Fig. 1d,e).
GH-induced IGF-1 is one of the major hormones regulating neonatal growth20. To determine if altered IGF-1
expression contributes to the neonatal growth and bone defects in ksr2−/− mice, serum GH and IGF-1 levels in
PN6 and PN17 WT and ksr2−/− mice were measured by ELISA. Compared to WT offspring, ksr2−/− mice show
no significant differences in GH levels at both PN6 and PN17 (Fig. 1f). However, serum IGF-1 is 35% and 65%
lower in ksr2−/− mice compared to WT littermates at PN6 and PN17, respectively (Fig. 1g). As measured by
qPCR, IGF-1 mRNA is decreased by 36% and 43% in the liver of ksr2−/− mice at PN6 and PN17, respectively
(Fig. 1h). Expression of serum IGF binding proteins (IGFBPs) was also measured. As observed previously by
ligand blotting, the major IGFBPs expressed in the serum of neonatal mice are IGFBP2 and IGFBP3 23. Whereas
IGFBP2 expression dominates in the early postnatal period, its serum concentration declines after PN14 in WT
mice (Fig. 1i, top panel). However, in the ksr2−/− mice, this decrease is delayed by several days and does not
occur until after PN17 (Fig. 1i, bottom panel). IGFBP3 becomes the dominant serum IGFBP in adult mice, and
serum IGFBP3 is low in ksr2−/− mice as compared to WT mice at 6 weeks of age. Compared to WT mice, liver
IGFBP2 mRNA levels are up-regulated, and IGFBP3 mRNA levels are down-regulated in ksr2−/− mice at PN17
(Fig. 1j). Elevated IGFBP2 and decreased IGFBP3 are consistent with the reduction in GH signaling observed in
ksr2−/− mice24. These results show that KSR2 is required for GH-induced hepatic IGF-1 production and regulation of the IGF-1/IGFBP axis in neonatal mice.

FGF21 is elevated in neonatal ksr2−/− mice. FGF21 induces liver Suppressor of Cytokine Signaling 2
(SOCS2) overexpression to inhibit GH receptor signaling, subsequently decreasing IGF-1 mRNA expression in
hepatocytes22,25. High levels of FGF21 have also been reported to cause bone loss by potentiating PPARγ activity26.
Importantly, FGF21 transgenic mice have normal birth weights, but they exhibit stunted neonatal growth and
decreased blood IGF-1 levels22, similar phenotypic characteristics to those observed in ksr2−/− mice. Relative to
WT mice, FGF21 is increased 2.4- and 4.4-fold in the sera of PN6 and PN17 ksr2−/− mice, respectively (Fig. 2a).
Hepatic FGF21 mRNA levels are slightly, but not significantly, elevated in ksr2−/− mice at PN6. However, in PN17
ksr2−/− mice, the levels of FGF21 are elevated 4-fold above WT levels (Fig. 2b). It is important to note that FGF21
levels in both ksr2−/− and WT mice at PN17 are significantly lower compared to those at PN6 (Fig. 2a,b). This
decline of FGF21 mRNA expression in the liver and of FGF21 protein levels in the sera of mice from ages PN6 to
PN17 is consistent with a previous report27.
FGF21 disruption does not rescue the neonatal growth defect of ksr2−/− mice.

To evaluate if
elevated FGF21 levels cause the growth defects and GH resistance in ksr2−/− mice, fgf21−/− mice (a gift from
Dr. Steven A. Kliewer, UT Southwestern) were crossed with ksr2+/− mice to produce the fgf21−/− ksr2−/− mice.
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Figure 1. ksr2−/− mice exhibit low serum IGF-1 and neonatal growth defects. (a) PN17 WT and ksr2−/−
mice littermates. (b) Growth curves of WT and ksr2−/− mice from PN6 to PN17 (n = 11 WT group, n =  15
ksr2−/− group, two-way ANOVA with repeated measures Bonferoni post hoc test). (c–e) Nose-to-anus length
(c), bone mineral density (BMD) (d), and bone mineral content (BMC) (e) of WT and ksr2−/− male and female
mice at 5 weeks of age (n = 16, 15, 16, and 8, respectively). (f) Serum GH of WT and ksr2−/− mice at PN6 (n =  7
per group) and PN17 (n = 9 per group). (g) Serum IGF-1 of WT and ksr2−/− mice at PN6 and PN17. (n =  9, 7,
12, and 8, respectively). (h) Hepatic IGF-1 mRNA levels in WT and ksr2−/− mice at PN6 and PN17 (n =  6–7
per group). For comparison, IGF-1 levels of WT mice at PN6 were set to 1 and rps18 was used as an internal
control. (i) Analysis of serum IGFBPs from WT and ksr2−/− mice. Aliquots (0.5 μl) of serum prepared from
animals at the indicated postnatal times were subjected to ligand blot analysis probed with 125I-IGF2. The
data shown are representative of duplicate runs for each of 3 distinct sets of serum samples. (j) IGFBP2 and
IGFBP3 mRNA levels were measured by qPCR in PN17 liver tissue (n = 4–6 per group). Levels of WT mice
were set to 1. Rps18 was used as an internal control. Data are shown as mean ±  SEM. *p <  0.05, **p <  0.01,
***p <  0.001, ****p <  0.0001.
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Figure 2. FGF21 disruption does not rescue the neonatal growth defect of ksr2−/− mice. (a) Serum FGF21
levels in PN6 and PN17 WT and ksr2−/− littermates (n = 6–9 per group). (b) Hepatic FGF21 mRNA in PN6 and
PN17 WT and ksr2−/− littermates (n = 6, 6, 10, and 9 respectively). Levels of WT mice at PN6 were set to 1 and
rps18 was used as an internal control. (c) Growth curves of PN6 to PN17 WT, ksr2−/−, fgf21−/−, and fgf21−/−
ksr2−/− male and female mice (n = 10–15 per group, two- way ANOVA with repeated measures Bonferoni post
hoc test was used). (d–f) Nose-to-anus length (d), bone mineral density (e), and bone mineral content (f) of
male fgf21−/− and fgf21−/− ksr2−/− mice at 5 weeks of age (n = 8 per group). (g) Serum IGF-1 levels from male
and female mice of the indicated genotypes at PN6 (n = 9, 7, 5, and 7 respectively) and PN17 (n = 12, 8, 9, and
12, respectively). (h) Hepatic IGF-1 mRNA levels from male and female mice of the indicated genotypes at
PN6 (n = 4–6 per group) and PN17 (n = 7 per group). For comparison, IGF-1 levels of WT at PN6 were set to 1
and rps18 was used as an internal control. Data are shown as mean ±  SEM. *p <  0.05, **p <  0.01, ***p <  0.001,
****p <  0.0001
fgf21−/− ksr2−/− mice are the same size and grow at the same rate as ksr2−/− mice (Fig. 2c). At 5 weeks of age,
nose-to-anus length, BMD, and BMC of fgf21−/− ksr2−/− mice are significantly less than their fgf21−/− littermates
(Fig. 2d–f), and are consistent with levels seen in ksr2−/− mice (Fig. 1c–e). There are no detectable differences in
serum IGF-1 (Fig. 2g) or hepatic IGF-1 mRNA (Fig. 2h) between fgf21−/− ksr2−/− mice and ksr2−/− mice at both
PN6 and PN17. This suggests that, although elevated blood FGF21 can inhibit IGF-1 expression, removing FGF21
does not increase IGF-1 levels in ksr2−/− mice. In addition, the serum IGF-1 levels in fgf21−/− mice are comparable with the levels of WT mice (Figs 1g and 2g) and consistent with previous reports28. These results suggest that
elevated serum FGF21 is not the source of the growth and bone defects in ksr2−/− neonatal mice.
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Exogenous IGF-1 restores body length and bone development, but not body mass in ksr2−/−
pups. To determine if low IGF-1 levels are responsible for the growth defects observed in ksr2−/− mice,

we expressed IGF-1 in vivo by injecting adenovirus expressing human IGF-1 (Ad5RSV-IGF-1) in newborn
pups (PN2) by retro-orbital injection29. Compared to the control-injected (Ad5RSV-eGFP) ksr2−/− mice, the
Ad5RSV-IGF-1 injection failed to rescue the body mass of ksr2−/− mice during the neonatal period (Fig. 3a). We
measured liver IGF-1 mRNA expression in ksr2+/− mice to confirm the expression of human IGF-1 (hIGF-1) via
adenovirus. When measured 3 days after adenovirus injection (PN5), total IGF-1 mRNA (including both mouse
endogenous mRNA and virally expressed human IGF-1) in mice injected with Ad5RSV-IGF-1 was markedly
increased as compared to mice injected with the Ad5RSV-eGFP (Fig. 3b). Although body mass is not improved
by adenovirus-mediated increased IGF-1 expression, at 5 weeks of age, Ad5RSV-IGF-1 normalizes nose-to-anus
length, BMC, and BMD in female (Fig. 3c–e) and BMD in male ksr2−/− mice (Fig. 3g–i) while having no significant effect on WT mice. These data are consistent with observations that serum IGF-1 is important for bone
growth and bone density30,31. Our results suggest that serum IGF-1 contributes to neonatal skeleton development,
but is not the only factor resulting in the decreased whole-body mass in ksr2−/− mice.

A cell non-autonomous action of KSR2 promotes GH signaling in the liver.

To explore the role
of KSR2 in GH-stimulated IGF-1 expression during the neonatal period, we studied GH signaling in ksr2−/−
hepatocytes. GH binding induces a conformational change in dimerized growth hormone receptor (GHR)
leading to the transactivation of JAK232,33 and phosphorylation of STAT5b, which is the major transcription
factor driving GH-stimulated IGF-1 gene expression34. To understand the molecular mechanisms behind the
decreased IGF-1 expression in the livers of neonatal ksr2−/− mice, we injected GH intraperitoneally into PN17
WT and ksr2−/− mice, euthanized the mice after 15 min, and prepared liver tissue for western blot analysis.
Phosphorylation of both JAK2 and STAT5 is increased in the livers of WT mice in response to GH injection.
However, in ksr2−/− mice, GH-stimulated phosphorylation of JAK2 and STAT5 is substantially attenuated compared to their WT littermate controls (Fig. 4a). To further establish that STAT5b activity is decreased in neonatal
ksr2−/− mice, mRNA levels for the STAT5b gene targets ALS, MUP3, and MUP1/2/6/8 were measured by qPCR
and shown to be down-regulated in ksr2−/− mice compared to their WT littermates (Fig. 4b). These results suggest
that the decreased blood IGF-1 levels in ksr2−/− mice may be caused by suppressed GH signaling as represented
by decreased JAK2 and STAT5b activities. However, the impaired GH signaling is not due to elevated expression of SOCS, as the ksr2−/− liver expresses normal amounts of SOCS1-3 and the related Cytokine-Inducible
SH2-containing (CIS) mRNA (Fig. 4c). To determine the extent to which KSR2 disruption affects GH signaling
throughout the body, we also examined STAT5 phosphorylation in quadriceps muscle. GH stimulation induced
similar STAT5 phosphorylation in WT and ksr2−/− mice (Fig. 4d). Furthermore, IGF-1 mRNA levels from skeletal
muscle, heart, and kidney in WT and ksr2−/− mice at PN17 were not different (Fig. 4e). These data suggest that the
GH resistance is specific to the liver.
To further understand how KSR2 regulates GH signaling specifically in the liver, primary hepatocytes were
isolated from PN17 WT and ksr2−/− livers and treated with 100 ng/ml of GH, and the cells were lysed. No difference was observed in STAT5b phosphorylation between WT and ksr2−/− hepatocytes in response to GH stimulation (Fig. 4f), suggesting that KSR2 acts in a cell non-autonomous manner to regulate liver GH signaling.

Discussion

The molecular mechanisms that underlie postnatal development have been studied extensively, but remain
incompletely understood. As an extension of fetal development in mice, the postnatal period is important in
initiating developmental plasticity11. Our data indicate that KSR2 functions in a cell non-autonomous fashion
to promote postnatal signaling that optimizes growth hormone (GH)-stimulated hepatic IGF-1 expression. The
reduced expression of IGF-1 in ksr2−/− neonatal mice appears to account for defects in bone development and
body length in these mice, but does not account for their reduced body mass. The developmental growth defect
displayed by neonatal ksr2−/− mice during the first three weeks of life is followed by accelerated weight gain that
leads to obesity and insulin resistance in adult mice12,13. The effect of KSR2 on these developmental changes raises
the possibility that the function of this molecular scaffold during the postnatal period affects adult metabolism.
Despite the fact that ksr2−/− mice are born normal in size, the effects of KSR2 disruption show a striking
similarity to the effects of intrauterine growth retardation (IUGR) on the IGF-1/IGFBP axis. IUGR is associated
with a state of GH resistance, which is characterized by increased GH and reduced IGF-1 concentrations35. IUGR
models show decreased IGF-1 from day 22 of gestation to postnatal day 9, but IGF-1 levels were not different at
later time points36. Similarly, ksr2−/− mice have low IGF-1 levels from PN6 to PN17 (Fig. 1), yet do not show significant differences in IGF-1 expression in adulthood (data not shown). Non-catch-up growth (NCG) in children
born small for gestational age (SGA) is associated with GH resistance37–40. Similar to the effect of KSR2 disruption
in mouse pups (Fig. 4), uterine artery ligation in pregnant rats to induce NCG-SGA also impaired GH-stimulated
JAK2 and STAT5 phosphorylation39. IUGR children have lower serum IGFBP3 than lean children of normal
height41, while postnatal ksr2−/− mice also show decreased IGFBP3 (Fig. 3). These defects in GH signaling and
IGF-1 and IGFBP expression suggest that KSR2 deletion disrupts a physiological pathway also impaired by IUGR.
However, the fact that ksr2−/− mice develop normally in utero suggests that the small size in rodent models of
IUGR may not be the only trigger for altered postnatal programming of the GH/IGF-1 axis.
Rescue of growth in IUGR infants has been attempted by treatment with IGF-1 without consistent conclusions. Maternal administration of IGF-1 during the second half of pregnancy improves maternal weight, but not
fetal and placental weights42,43. Transamniotic administration of recombinant hIGF-1 increased serum IGF-1 levels, but failed to significantly increase fetus weight44. However, fetal birth weight was increased by intraplacental
injection of an Ad-IGF-1 gene in an IUGR rabbit model45. Our studies show that body mass cannot be rescued in
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Figure 3. Exogenous IGF-1 rescues the defects in length and bone development, but not the mass of
ksr2−/− mice. (a) Growth curves of WT and ksr2−/− injected with AdRSVeGFP (Ad-EGFP) or AdRSVhIGF-1
(Ad-IGF-1) adenovirus at PN2 (n = 16–21 per group, two-way ANOVA with repeated measures Bonferoni post
hoc test was used). (b) Total IGF-1 (mouse and human) mRNA expression in PN5 ksr2+/− liver (n =  4–6 per
group). For comparison, the average IGF-1 mRNA level of Ad-EGFP-injected PN5 mice was set to 1. Rps18 was
used as an internal control. (c–e). Nose-to-anus length (c), bone mineral density (d), and bone mineral content
(e) at 5 weeks of age of WT and ksr2−/− female mice injected with control or IGF-1-encoding adenovirus
(n = 17, 7, 8, and 10 respectively). (f–h) Nose-to-anus length (f), bone mineral density (g), and bone mineral
content (h) at 5 weeks of age of WT and ksr2−/− male mice injected with control or IGF-1-encoding adenovirus
(n = 10, 10, 3, 3, respectively). One-way ANOVA with Bonferroni post-test with multiple comparisons was
used to analyze the data in panels c-h. Data are shown as mean ±  SEM. *p <  0.05, **p <  0.01, ***p <  0.001,
****p <  0.0001.

ksr2−/− mice using Ad-IGF-1 during the neonatal period, though bone length, BMC, and BMD were restored to
normal. These data suggest that additional KSR2-dependent factors contribute to normal neonatal development.
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Figure 4. A cell non-autonomous action of KSR2 is required for GH signaling in the liver. (a) Hepatic
STAT5b and JAK2 phosphorylation in PN17 WT and ksr2−/− mice 15 min after IP injection of PBS or 125 μg/kg
recombinant human GH. Liver tissue was lysed and analyzed via western blot with the indicated antibodies.
The ratio of phosphorylation to total STAT5 and JAK2 was analyzed by LI-COR Odyssey system (n =  4–5
per group). Quantification is shown to the right of the western blot. (b) STAT5 target genes ALS, MUP3, and
MUP1/2/6/8 were measured in livers from PN17 WT and ksr2−/− mice (n = 4–6 per group). WT levels were
set to 1. *p <  0.05, **p <  0.01. (c) qPCR of SOCS1-3 and CIS mRNAs from WT and ksr2−/− liver (n =  6–8
per group). For comparison, levels of WT were set to 1 and rps18 was used as an internal control. (d) Muscle
STAT5b phosphorylation in PN17 WT and ksr2−/− mice treated as in panel a. (e) IGF-1 mRNA levels from
kidney, heart, and muscle of PN17 WT and ksr2−/− mice (n = 3–4 per group). IGF-1 levels of WT were set to 1,
and 18srRNA was used as an internal control. (f) STAT5 phosphorylation in primary hepatocytes from PN17
WT and ksr2−/− liver treated for 5 min with 100 ng/ml GH. Results are representative of three independent
experiments. Data are shown as mean ±  SEM. *p <  0.05, **p <  0.01.

Nutritional and metabolic status regulates the GH/IGF-1 axis through the liver by modulating liver sensitivity
to GH46. FGF21, a member of the endocrine FGF superfamily, regulates growth and causes GH resistance under
nutrient-deprived conditions. FGF21 is considered a starvation signal that mediates adaptive responses based
on nutritional status22,28. FGF21 transgenic mice have a normal birth weight, but are significantly smaller than
WT mice at three weeks of age22. ksr2−/− mice showed higher FGF21 expression during the neonatal period
(Fig. 2). Collectively, the growth similarities between neonatal ksr2−/− mice and neonatal FGF21 transgenic mice
suggested that the elevated expression of FGF21 could underlie the GH resistance in ksr2−/− mice. However,
the fgf21−/−ksr2−/− mice are still smaller than WT mice and maintain a growth rate similar to ksr2−/− mice.
FGF21-induced GH resistance is mediated partly by SOCS2 overexpression22. However, ksr2−/− mice have normal liver levels of SOCS and CIS. These observations, along with suppressed IGF-1 expression in the fgf21−/−
ksr2−/− mice, demonstrate that elevated FGF21 is not responsible for defective GH signaling in ksr2−/− mice.
The mechanism by which FGF21 is increased in ksr2−/− neonatal mice is unknown. However, its acute elevation may offer clues regarding the stress caused by disruption of KSR2 in neonates. The function of neonatal
FGF21 may be different from adult FGF21, as fasting cannot induce increased FGF21 expression in unfed or
undernourished newborn pups as it does in adult mice27. Instead, the increase in neonatal FGF21 is induced by
a high-fat diet and by milk intake. The increased FGF21 may suggest that neonatal ksr2−/− mice have normal
milk intake, which is consistent with the detection of milk in the stomachs of PN6 and PN17 ksr2−/− mice when
euthanized. Neonatal FGF21 is considered to be a food intake-dependent signal that favors neonatal brown adipose tissue thermogenic activation. ksr2−/− mice have defective thermogenesis12, and the increased FGF21 may
reflect a compensatory attempt to increase ksr2−/− thermogenesis and promote survival. Human preterm infants
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have high FGF21 expression that is inversely related to infant height47. These observations suggest that, though
elevated FGF21 does not affect neonatal growth in ksr2−/− mice, it may be beneficial for survival.
GH signaling is defective in the liver but not in the skeletal muscle of ksr2−/− mice (Fig. 4), revealing a specific
role for KSR2 in regulating hepatic GH signaling in neonates. This observation likely excludes KSR2-dependent
regulation of circulating GH, for example, via growth hormone binding protein48,49. However, the fact that GH
signaling is defective in the livers of ksr2−/− mice but not in isolated primary ksr2−/− hepatocytes indicates a cell
non-autonomous action of KSR2 in regulating hepatic GH signaling. Thus, KSR2 is likely to affect GH activation
of STAT5 indirectly via a nervous or hormonal mechanism that directly affects hepatic GH signaling. KSR2 is
expressed primarily in brain12,17. It is possible that the lack of KSR2 provides an inappropriate signal, or fails to
send a necessary signal, on the metabolic status in the brain to the liver. This raises the possibility that the obesity
observed in adult ksr2−/− mice is a consequence of KSR2’s action in the brain or a tissue other than adipocytes.
Indeed, KSR2 mRNA is barely detectable in white adipose tissue12. However, exogenous IGF-1 expression, even
though it rescues body length, BMC, and BMD, does not prevent obesity in ksr2−/− mice. Thus, the obesity of
ksr2−/− mice cannot be ascribed to the suppression of IGF-1 expression. The mechanisms through which KSR2
regulates body mass remain unclear. If KSR2 contributes to postnatal programming of adult metabolism, its
control over neonatal body mass may be a key contributor. In combination with previous reports12,13,19,50,51, these
data show that KSR2 plays a critical role in organismal growth and metabolism immediately after birth and in
adulthood. Defining the physiological mechanisms that mediate KSR2′s action will reveal the extent to which its
role in postnatal development contributes to adult energy balance.

Methods

Generation and housing of mice. ksr2−/− mice were generated by standard techniques targeting exon 4 of

the ksr2 locus12. Mice were backcrossed for >10 generations onto the C57BL/6J background as described previously13. fgf21−/− mice were a gift from Dr. Steven A. Kliewer (UT Southwestern). fgf21−/− mice were backcrossed
for 7 generations, then crossed with ksr2+/− mice. fgf21−/− ksr2−/− mice were generated from fgf21−/− ksr2+/−
matings. All study protocols were approved by the Institutional Animal Care and Use Committee (University
of Nebraska Medical Center, Omaha, NE) and were performed in accordance with federal, state, local, and
Association for Assessment and Accreditation of Laboratory Animal Care guidelines. Animals were maintained
on a 12 h light/dark schedule with free access to water and laboratory chow (Harlan Teklad 7912).

Bone mineral content (BMC) and bone mineral density (BMD) measurements.

Mice at five
weeks of age were anesthetized with isoflurane, nose-to-anus lengths were measured, and the Lunar PIXImus
Densitometer (GE Medical Systems) dual energy x-ray absorptiometry (DEXA) was used to measure and calculate total body (exclusive of the head region) BMC and BMD.

Adenovirus experiments. Ad5RSV-eGFP and Ad5RSV-IGF-1 vectors, expressing EGFP and human IGF-1,

respectively, were purchased from the University of Iowa Viral Vector Core Facility. Viral titers were 6 ×  1010 pfu/ml.
Postnatal day 2 (PN2) pups were injected with EGFP-expressing control or IGF-1-expressing virus (4.8 ×  108 pfu
virus in 20 μl total volume per mouse) once by retro-orbital injection according to the method described previously29.
Litter sizes of 4–8 were used for the study. Weights were measured every other day from PN4 to PN17.

Quantitative PCR.

Mice were euthanized by CO2 inhalation and cervical dislocation at PN17 and older, or
by CO2 inhalation and decapitation at PN6. Tissues removed from WT and ksr2−/− mice were immediately frozen
on dry ice or in liquid nitrogen and stored at −80 °C. RNA was extracted using TRI Reagent (Molecular Research
Center) and the RNeasy kit (Qiagen). After subsequent treatment with DNase I (Ambion, AM1906), cDNA
was synthesized using iScript RT Supermix (BioRad) according the manufacturer’s instructions. Quantitative
real-time PCR (qPCR) was performed in a total reaction volume of 20 μl using SsoAdvanced Sybr Green
Supermix (BioRad) according to the manufacturer’s instructions. All PCR reactions were performed in duplicate
on a Stratagene MxPro3000p detection system, and relative mRNA levels were calculated by the comparative
threshold cycle method by using rps18 or 18S rRNA as an internal control. The primer sequences of MUP3 and
MUP1/2/6/8 were described previously52.
FGF21: 5′-CTACCAAGCATACCCCATCC-3′and 5′-GCCTACCACTGTTCCATCCT-3′
IGF-1: 5′-TGGATGCTCTTCAGTTCGTG-3′and 5′-ATCCACAATGCCTGTCTGAG-3′
m+hIGF-1: 5′-AGCAGTCTTCCAACCCAATTA-3′and 5′-AGGTAGAAGAGATGCGAGGA-3′
18s rRNA: 5′-GTAACCCGTTGAACCCCATT-3′and 5′- CCATCCAATCGGTAGTAGCG-3′
rps18: 5′-CATGCAGAACCCACGACAGTA-3′and 5′-CCTCACGCAGCTTGTTGTCTA-3′
IGFALS: 5′-GTACAAGGAACAATGGCTCTGA-3′and 5′-CTGATGCTCCAGGATCTGTC-3′
MUP3: 5′-AAGAGTGCACCGAAATGACTG3′and 5′-TGCCAGCCTTTTCTGTTTGTT-3′
MUP1/2/6/8: 5′-GACTTTTTCTGGAGCAAATCCATG-3′and 5′-GAGCACTCTTCATCTCTTACAG-3′
SOCS1: 5′-CAGAAAAATGAAGCCAGAGACC-3′and 5′-ATTCCACTCCTACCTCTCCAT-3′
SOCS2: 5′-AATGGTGTGGCAAAGTCTCT-3′and 5′-CGCCCTCAAGATCCCTT-3′
SOCS3: 5′-TTGTCGGAAGACTGTCAACG-3′and 5′-GGCTGGATTTTTGTGCTTGT-3′
CIS: 5′-CCGCCCAATTTGCTCCA-3′and 5′-GCTCCTTTCTCCTTCCATCC-3′

ELISA. Serum FGF21, GH, and human and mouse IGF-1 levels were measured using a Rat/Mouse FGF21
ELISA kit (Millipore, EZRMFGF21-26K), mouse GH ELISA kit (Millipore, EZRMGH-45K), and mouse IGF-1
ELISA kit (Alpco Immunoassays, 22-IG1MS-E01), respectively. Assays were performed according to the manufacturer’s instructions.
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Western blot.

Mice received intraperitoneal injections of 125 μg/kg recombinant human GH in 50 μl PBS.
Mice were euthanized 15 minutes after injection. Liver and quadriceps muscle were lysed in lysis buffer containing 25 mM Tris (pH 7.4), 125 mM NaCl, 1 mM MgCl2, and 1% NP40 with 2 mM EDTA, 10 mM NaF, 10 μg/ml
aprotinin, 20 μM leupeptin, 0.5 mM Na3VO4, 10 mM β-glycerophosphate, and 1 mM PMSF. Phosphorylation
of STAT5b and JAK2 was analyzed via western blot as described previously12 with the indicated antibodies. The
primary antibodies included STAT5 (Santa Cruz, SC1656), p-STAT5 (Cell Signaling, 9351S), JAK2 (Millipore,
04-001), p-JAK2 (Cell Signaling, 8082S), αtubulin (Santa Cruz, SC23948), and βactin (Santa Cruz, SC47778).
Proteins were detected and analyzed using the Odyssey Imaging System (Li-COR).

Primary hepatocyte culture. Primary hepatocytes were cultured as previously described with the following modifications53,54. Livers from PN17 neonates were carefully removed and put into Krebs-Ringer HEPES
(KRH) buffer (25 mM HEPES, 115 mM NaCl, 5 mM KCl, and 1 mM KH2PO4) with 5 mM EDTA under continuous gassing (O2:CO2 = 19:1) and agitated at 100 rpm for 30 min. Livers were rinsed and digested with
40 mg/100 ml collagenase (Sigma, C2139) in KRH buffer with 1 mM CaCl2 and agitated at 100 rpm for 1 h. Tissues
were triturated to facilitate tissue disaggregation. Suspension buffer (KRH buffer with 0.02 g/ml BSA and 2 mM
CaCl2) was added and liver digests were filtered through 70-μm filters (Becton Dickinson). Cells were washed
sequentially by centrifugation at low speed with suspension buffer, suspension buffer with 45% Percoll, and
suspension buffer. The final cell pellets were resuspended in Williams Complete Medium and cell viability was
assessed by trypan-blue exclusion. Viable cells were plated at 150,000 cells per well on 24-well plates coated with
Collagen IV (Sigma C-7521).
IGF Binding Protein (IGFBP) Ligand Blotting. IGFBP levels were determined by ligand blotting accord-

ing to a modified version of the method described previously55. Aliquots of mouse serum (0.5 μl each) were run
on 13% uniform or 8–18% gradient acrylamide gels under non-reducing conditions and then transblotted to
BA85 nitrocellulose. The blots were processed as described previously, then incubated with ~650,000 cpm/ml
125
I-IGF-2 for 16–20 h at 4 °C. Washed blots were visualized by autoradiography. The major IGFBPs expressed in
mouse serum were identified by their electrophoretic mobility based on precedent23.

Statistics. Data are presented as mean ± SEM. Data were analyzed for statistical significance using the
unpaired, two-tailed Student’s t-test for two group comparisons or ANOVA with the Bonferroni post-hoc test for
comparisons with more than two groups (GraphPad Prism). Statistical significance is specified for p values less
than or equal to 0.05.
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